Horizon Pharma | HZNP

Stock Price
99.67
Daily Change
-0.26%
Yearly
14.27%
Q2 Forecast
96.40
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 4,497.00 29.00 0.65% 23.24%
AbbVie 136.86 -0.01 -0.01% -6.60%
ALKERMES 29.46 -0.05 -0.17% 3.95%
Amgen 221.88 3.81 1.75% -9.60%
AstraZeneca 11,794.00 46.00 0.39% 17.10%
Bristol-Myers Squibb 65.98 0.32 0.49% -12.32%
Cara Therapeutics 3.16 0.07 2.27% -62.47%
Coherus Biosciences 4.98 0.53 11.91% -34.21%
Endo International 0.06 0.03 93.33% -87.57%
Horizon Pharma 99.67 -0.26 -0.26% 14.27%
Eli Lilly 444.26 1.93 0.44% 46.45%
Merck & Co 113.11 0.59 0.52% 25.90%
Novartis 90.38 1.01 1.13% 5.18%
Prestige Brands 56.28 -2.22 -3.79% -0.34%
Pacira 38.55 -0.54 -1.38% -36.43%
Pfizer 38.65 0.29 0.76% -27.43%
Perrigo 33.03 0.04 0.12% -15.98%
Revance Therapeutics 31.18 0.12 0.39% 137.11%
Supernus Pharmaceuticals 33.68 0.15 0.45% 20.41%
Bausch Health Companies 10.67 -0.39 -3.53% -7.70%
Xeris Pharmaceuticals 2.84 0.02 0.71% 36.54%
Zoetis 171.12 -0.76 -0.44% 0.06%

Indexes Price Day Year
USND 13229 -11.34 -0.09% 9.68%
US2000 1807 -24.19 -1.32% -4.40%

Horizon Pharma

Horizon Pharma traded at $99.67 this Monday June 5th, decreasing $0.26 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, Horizon Pharma lost 10.08 percent. Over the last 12 months, its price rose by 14.27 percent. Looking ahead, we forecast Horizon Pharma to be priced at 96.40 by the end of this quarter and at 86.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.